This Hep C Rx Combo May Be Quicker Cure
For people with hepatitis C, three isn't a crowd. These patients got well much faster with the addition of a third medication.
Cirrhosis: Usually Preventable but Common
Cirrhosis of the liver may usually be preventable, but it may be more common than previously thought. Fortunately, patients can take simple steps to keep their livers in tip-top shape.
FDA Approves New Combo Treatment for Hep C
In recent years, people with hepatitis C have gained several new treatment options. The US Food and Drug Administration (FDA) has added another option to the list.
FDA Approves Viekira Pak to Treat Hepatitis C
The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis.
Gilead Announces Harvoni Results from Phase 2 and Phase 3 Studies
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals.
Hepatitis C Patients May Live Longer With Treatment
For patients with chronic hepatitis C, liver problems can sometimes shorten their lives. But a new study found that successful treatment might ease some life expectancy concerns for these patients.
FDA Approves Combo Treatment for Hepatitis C
The US Food and Drug Administration (FDA) approved a new combination treatment for hepatitis C infection Wednesday.
Hepatitis C Rx Gets Additional Approval as Combo Treatment with Sofosbuvir
Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved OLYSIO® (simeprevir), a hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen.
FDA Approves New Combo Rx for Hepatitis C
US regulators have approved a new pill to treat hepatitis C. That pill, which is a combination of two medications, could simplify treatment for patients.
FDA Approves First Combination Pill to Treat Hepatitis C
The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.